Relic Life Science last traded at ₹66.50 (2026-10-13). Over the past month the stock moved -11.3%, three months the stock moved -3.9%, year the stock moved -18.9%. Its closing range over 52 weeks is ₹62.80 – ₹84.99, with the latest close 21.8% below the high.
Closing prices up to 2026-10-13.
Incorporated in 1991, Relic Technologies Ltd is engaged in share broking business[1]
Business Overview:[1][2][3] RTL is an integrated business, primarily engaged in Corporate & Institutional broking business related to Capital Markets and Equities Investments. It has a NSE corporate membership and they serve Institutional clients
In the latest quarter (Jun 2026), Relic Life Science reported sales of ₹0.35 crore (-72.7%) and net profit of ₹-1.03 crore, compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 0.35 | -1.16 | -331.43 | -1.03 | -1.16 |
| Mar 2026 | 0.47 | -0.97 | -206.38 | -2.93 | -3.59 |
| Dec 2025 | 0.32 | -1.64 | -512.50 | -0.48 | -0.50 |
| Sep 2025 | 0.60 | -0.86 | -143.33 | 0.16 | 0.31 |
| Jun 2025 | 1.28 | -1.44 | -112.50 | -3.69 | -6.29 |
| Mar 2025 | 0.47 | -0.30 | -63.83 | -0.53 | -1.22 |
| Dec 2024 | 0.47 | -0.96 | -204.26 | -1.00 | -2.78 |
| Sep 2024 | 0.63 | 0.17 | 26.98 | 0.14 | 0.39 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +110.0% | +11.9% | +23.7% | +212.2% | -4.8% | -31.9% | +0.0% | -72.7% |
| Operating profit growth | – | – | – | – | -605.9% | – | – | – |
| Net profit growth | – | – | – | – | +14.3% | – | – | – |
| EPS growth | – | – | – | – | -20.5% | – | – | – |
| OPM % | 27.0% | -204.3% | -63.8% | -112.5% | -143.3% | -512.5% | -206.4% | -331.4% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
In the latest year (Mar 2026), Relic Life Science reported sales of ₹2.67 crore (+34.8%) and net profit of ₹-6.95 crore, compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 2.67 | -4.90 | -183.52 | -6.95 | -9.60 |
| Mar 2025 | 1.98 | -1.17 | -59.09 | -1.49 | -4.14 |
| Mar 2024 | 1.64 | -0.69 | -42.07 | -0.90 | -2.50 |
| Mar 2023 | 1.57 | 0.46 | 29.30 | 0.23 | 0.64 |
| Mar 2022 | 1.83 | 0.66 | 36.07 | 0.43 | 1.19 |
| Mar 2021 | 1.39 | 0.53 | 38.13 | 0.39 | 1.08 |
| Mar 2020 | 1.05 | 0.24 | 22.86 | 0.06 | 0.17 |
| Mar 2019 | 2.28 | 1.50 | 65.79 | 0.97 | 2.69 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +91.6% | -53.9% | +32.4% | +31.7% | -14.2% | +4.5% | +20.7% | +34.8% |
| Operating profit growth | +219.1% | -84.0% | +120.8% | +24.5% | -30.3% | -250.0% | – | – |
| Net profit growth | +410.5% | -93.8% | +550.0% | +10.3% | -46.5% | -491.3% | – | – |
| EPS growth | +407.5% | -93.7% | +535.3% | +10.2% | -46.2% | -490.6% | – | – |
| OPM % | 65.8% | 22.9% | 38.1% | 36.1% | 29.3% | -42.1% | -59.1% | -183.5% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
No AI analysis generated yet for Relic Life Science.
Get Free AI Stock Analysis FREE →No recent news available for Relic Life Science.
Relic Life Science shares were last quoted at ₹66.50 (-5.5% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
Relic Life Science has a price-to-earnings (P/E) ratio of 53.13 and a price-to-book (P/B) ratio of 2.01. The industry P/E is 40.24.
The 52-week high of Relic Life Science is ₹91.45 and the 52-week low is ₹52.02.
The market capitalisation of Relic Life Science is about ₹35.03 crore.
In the latest quarter (Jun 2026), Relic Life Science reported sales of ₹0.35 crore (-72.7%) and net profit of ₹-1.03 crore, compared with the same quarter last year.
This page is for information and is not investment advice. As per the data shown here, Relic Life Science has a 3-year ROE of -23.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
Promoters hold about 44.93% of Relic Life Science.
Relic Life Science belongs to the Finance - Investment sector.